Professor Michael Barry:

Yes. I am very familiar with Professor Postma and what is happening in the Netherlands. As he said, we actually compare very well. In broader terms in relation to early access, I made the point earlier that if you are willing to look at early access for cancer drugs, you have to look beyond that. It would be hard to defend not looking at early access for orphan drugs, and more widely.